Campbell & Co Investment Adviser’s CorMedix CRMD Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$77.4K	Sell	11,398 -93,430	-89%	-$691K	﹤0.01%	1006
2025 Q4	$1.22M	Buy	104,828 +66,604	+174%	+$736K	0.06%	487
2025 Q3	$445K	Buy	38,224 +24,923	+187%	+$301K	0.03%	783
2025 Q2	$164K	Sell	13,301 -14,950	-53%	-$165K	0.01%	1078
2025 Q1	$174K	Sell	28,251 -33,101	-54%	-$343K	0.01%	959
2024 Q4	$497K	Sell	61,352 -16,993	-22%	-$170K	0.04%	660
2024 Q3	$633K	Buy	+78,345	New	+$424K	0.05%	615

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Campbell & Co Investment Adviser's CRMD Position: Q1 2026 in Review

Campbell & Co Investment Adviser reduced its CorMedix (CRMD) stake by 89% in Q1 2026, selling an estimated $691K and leaving 11,398 shares worth $77.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

Campbell & Co Investment Adviser first reported a position in CRMD in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.22M in Q4 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

Campbell & Co Investment Adviser held 11,398 shares of CorMedix worth $77.4K as of Q1 2026.
Campbell & Co Investment Adviser sold 93,430 CorMedix shares in Q1 2026, an estimated $691K.
CorMedix made up ﹤0.01% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #1006 holding.
Campbell & Co Investment Adviser first reported a position in CorMedix in Q3 2024 and has held it in 7 quarters since.
Campbell & Co Investment Adviser's CorMedix position peaked at $1.22M in Q4 2025.
187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.